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Mutations in Sigma 1 receptor (SIGMAR1) have been previously identiﬁed in patients with amyotrophic lateral sclerosis and
disruption of Sigmar1 in mouse leads to locomotor deﬁcits. However, cellular mechanisms underlying motor phenotypes in human
and mouse with disturbed SIGMAR1 function have not been described so far. Here we used a combination of in vivo and in vitro
approaches to investigate the role of SIGMAR1 in motor neuron biology. Characterization of Sigmar1/ mice revealed that
affected animals display locomotor deﬁcits associated with muscle weakness, axonal degeneration and motor neuron loss. Using
primary motor neuron cultures, we observed that pharmacological or genetic inactivation of SIGMAR1 led to motor neuron
axonal degeneration followed by cell death. Disruption of SIGMAR1 function in motor neurons disturbed endoplasmic reticulum–
mitochondria contacts, affected intracellular calcium signalling and was accompanied by activation of endoplasmic reticulum stress
and defects in mitochondrial dynamics and transport. These defects were not observed in cultured sensory neurons, highlighting
the exacerbated sensitivity of motor neurons to SIGMAR1 function. Interestingly, the inhibition of mitochondrial ﬁssion was
sufﬁcient to induce mitochondria axonal transport defects as well as axonal degeneration similar to the changes observed after
SIGMAR1 inactivation or loss. Intracellular calcium scavenging and endoplasmic reticulum stress inhibition were able to restore
mitochondrial function and consequently prevent motor neuron degeneration. These results uncover the cellular mechanisms
underlying motor neuron degeneration mediated by loss of SIGMAR1 function and provide therapeutically relevant insight into
motor neuronal diseases.
1 Department of Medical Genetics, University of Lausanne, CH-1005 Lausanne, Switzerland
2 Neurodegenerative Studies Laboratory, Brain Mind Institute, Ecole Polytechnique Fe´de´rale de Lausanne (EPFL), CH-1015
Lausanne, Switzerland
3 Institute of Neuropathology, RWTH Aachen University, 52074 Aachen, Germany
4 Department of Neuroscience and Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
Correspondence to: Nathalie Bernard-Marissal,
Department of Medical Genetics,
Faculty of Biology and Medicine,
University of Lausanne,




doi:10.1093/brain/awv008 BRAIN 2015: 138; 875–890 | 875
Received July 8, 2014. Revised November 29, 2014. Accepted December 2, 2014. Advance Access publication February 12, 2015
 The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Correspondence may also be addressed to: Hamid Azzedine, E-mail: azzedine.hamid@yahoo.fr, hazzeddine@ukaachen.de; or Roman
Chrast, E-mail: Roman.Chrast@unil.ch, Roman.Chrast@ki.se
Keywords: Sigma 1 receptor; motor neuron degeneration; MAMs loss; mitochondrial and endoplasmic reticulum dysfunction
Abbreviations: ALS = amyotrophic lateral sclerosis; CHOP = C/EBP homologous protein; ER = endoplasmic reticulum;
MAM = mitochondria-associated membrane; PDI = protein disulphide isomerase
Introduction
Motor neuron diseases regroup incurable neurological dis-
orders characterized by the gradual and selective degener-
ation of motor neurons. Among them, amyotrophic lateral
sclerosis (ALS) is the most representative adult motor
neuron disease with an incidence rate of 2–3 per 100 000
(Al-Chalabi et al., 2012). Although the familial cases rep-
resent only 10% of all ALS cases, their characterization
led to substantial insight into the pathophysiology of ALS
(Sreedharan and Brown, 2013). Accumulating evidence
from mouse models of motor neuron disease implicated
synaptic pathology (Pun et al., 2006), mitochondrial dys-
function (Court and Coleman, 2012), calcium signalling
impairment (Bernard-Marissal et al., 2012), endoplasmic
reticulum (ER) stress (Saxena et al., 2009) and disturbances
of axonal transport (Bilsland et al., 2010) as critical factors
involved in motor neuron degeneration in ALS mouse
models.
Recently, mutations in SIGMAR1 have been identiﬁed in
frontotemporal lobar degeneration co-occurring with ALS
(FTLD-ALS) (Luty et al., 2010) and in juvenile ALS (Al-Saif
et al., 2011). SIGMAR1 is a chaperone protein located at
the interface between the ER and mitochondria, called
mitochondria-associated membranes (MAMs). These struc-
tures have been shown to be involved in the control of lipid
biosynthesis, mitochondrial division, calcium signalling and
dynamics of the two organelles (Hayashi et al., 2009). At
the MAMs, SIGMAR1 regulates the compartmentalization
and export of lipids such as cholesterol and galactocera-
mide as well as the transfer of calcium between ER and
mitochondria by chaperoning the inositol 1,4,5-trispho-
sphate receptor 3 (ITPR3, formerly known as IP3R3).
Once activated by IP3, ITPR3 release calcium, which is
immediately captured into mitochondria by the voltage-
dependent anion channel 1 (VDAC1) (Hayashi and Su,
2007). The knock-down of SIGMAR1 in vitro was
shown to lead to calcium homeostasis defects and ER
stress activation and to enhance apoptosis induced by
stress factors (Hayashi and Su, 2007; Prause et al., 2013).
The Sigmar1 knock-out mouse (Sigmar1 /) presents
motor disabilities as measured by evaluation of spontan-
eous locomotor activity or by rotarod test (Langa et al.,
2003; Mavlyutov et al., 2010). In spinal cord, SIGMAR1
is highly expressed in motor neurons and has been
observed at the subsurface cisternae of the ER at the level
of large cholinergic postsynaptic densities (Mavlyutov
et al., 2010). Crossing Sigmar1 / mice with the ALS
mouse model SOD1G93A exacerbated the motor phenotype
and accelerated the end stage of the disease (Mavlyutov
et al., 2013). Conversely, stimulating SIGMAR1 function
using the agonists Pre-084 or SA4503 has been shown pro-
tective in both in vitro and in vivo models of motor neuron
diseases (Mancuso et al., 2012; Ono et al., 2014).
Although these data strongly suggest a role of SIGMAR1
in motor neurons, the cellular mechanisms leading to motor
neuron degeneration in the context of disturbed SIGMAR1
function have not been characterized so far. In the present
study, we used in vivo and in vitro models of loss-of-func-
tion of SIGMAR1 to demonstrate the importance of cal-
cium homeostasis, and ER and mitochondrial function
regulation for maintenance of motor neuron integrity.
Materials and methods
Animals
We used the previously described B6;129S5-
Sigmar1Gt(OST422756)Lex knockout mice (Sigmar1 /)
(Mavlyutov et al., 2010) purchased from MMRRC.
Offspring was genotyped by separated PCR using the follow-
ing primers: wild-typeF 5’ TCTGAGTACGTGCTGCTCTTCG
3’ and wild-typeR 5’CAGAAATCTCAGCCCAGTATCG3’,
MTF 5’ TCTGAGTACGTGCTGCTCTTCG 3’ and MTR 5’
ATAAACCCTCTTGCAGTTGCATC 3’. For neuronal cul-
tures, embryos were collected from wild-type and Sigmar1 /
mice at gestational Day 12.5 (E12.5) or from rat wild-type
(Janvier Labs) at E14. For histological studies animals were
sacriﬁced at 2.5 and 5 months old. Animals were housed in a
controlled environment with a 12-h light/12-h dark cycle, with
free access to water and standard chow diet. All experiments
were performed in accordance with the legal requirements of
the University of Lausanne and the Canton de Vaud.
Behavioural studies
Rotarod studies were performed as previously described
(Dierssen et al., 2011). Mice (wild-type n = 8 and Sigmar1 /
n = 9 at 2.5 months old and wild-type n = 6 and Sigmar1 /
n = 7 at 5 months old) were placed on the rotating rod and chal-
lenged using the following steps: on Days 1 and 2,mice learned to
stay on the rotarod at constant speed of 5 rpm for 180 s. AtDay 3,
motor coordinationwas assessed on the accelerating rotarodwith
a rate of 4 to 50 rpm for 2.5min. For each trial, the time until the
mice fall off the rod was recorded. Data were expressed as
means standard error of the mean (SEM). Muscle strength
was measured by modiﬁed grid test on 5-month-old wild-type
and Sigmar1 / mice as previously described (Saxena et al.,
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2009). Mice were trained for 4 days before being scored. Their
ability to lift grids of 10, 20, 30 and 40 gwasmeasured three times
with a maximum duration of 60 s. Trials were separated by 15 s
pauses. The best score for each grid was kept.Muscle force values
correspond to the sum of times for each grid multiplied by the
weight of the grid. Data were expressed as means  SEM.
Primary cultures
Motor neuron cultures were prepared from E12.5 mice em-
bryos as previously described (Bernard-Marissal et al., 2012).
Brieﬂy, cells were dissociated mechanically after trypsin treat-
ment of the dissected spinal cords. The largest cells were iso-
lated using iodixanol density gradient puriﬁcation. After a ﬁnal
BSA cushion, motor neurons were plated onto poly-ornithine/
laminin-coated wells in Neurobasal medium (Invitrogen)
complemented with a mixture of neurotrophic factors (1 ng/
ml BDNF, 100 pg/ml GDNF, and 10 ng/ml CNTF), 2%
horse serum, B27 supplement (Invitrogen), 0.05mM
L-glutamine, 25mM glutamate, and 25mM mercaptoethanol.
Dorsal root ganglia dissociated cultures were performed as
previously described (Stendel et al., 2010). Dorsal root ganglia
were obtained from E14.5 rat embryos, digested enzymatically
(0.25% trypsin-EDTA; Invitrogen) and seeded on polyornithi-
nin/laminin-coated coverslips in Neurobasal medium contain-
ing 4 g/l D-glucose, 2% B27 supplement (Invitrogen), 2mM L-
glutamine and 50 ng/ml NGF.
Rat Schwann cell cultures were prepared as previously
described (Stendel et al., 2010). Postnatal Day 3 rat sciatic
nerves were dissociated in 4mg/ml collagenase type 1
(Sigma), 1.2mg/ml hyaluronidase (Sigma) and 0.3mg/ml tryp-
sin inhibitor (Sigma) in minimal essential medium at 37C for
60min. Subsequently, cells were plated on plastic dishes coated
with poly-L-lysine (Sigma) in Dulbecco’s modiﬁed Eagle
medium (DMEM) containing 10% foetal calf serum (FCS),
1% penicillin/streptomycin (Invitrogen) and 10 mM cytosine
arabinoside (Sigma). After 24 h, cells were washed and incu-
bated in Schwann cell growth medium [DMEM containing
10% FCS, 4 mg/ml crude glial growth factor (BioReba
Biotechnology) and 2mM forskolin (Sigma)]. Puriﬁcation of
rat Schwann cells to remove ﬁbroblasts was realized using
Thy1.1 antibody (AbD Serotec) and rabbit complement
(Sigma).
Except for neuronal survival experiments, rat neurons were
ﬁxed with paraformaldehyde (PFA 4%) 8 h after treatment or
at 16 h after plating for mouse neurons. Neuronal/Schwann
cells survival was assayed 24 h after treatment (rat neurons)
or seeding (mouse wild-type and Sigmar1 / neurons), re-
spectively by manual counting and also checked after using
SMI32 staining (motor neuronal marker).
Immunocytochemistry
Cultured cells were ﬁxed at indicated times with PFA 4% for
20min at 4C, then washed three times with phosphate-buf-
fered saline (PBS) and blocked in PBS (2% BSA, 2% heat-
inactivated goat serum, and 0.1% TritonTM X-100) for 1 h
at room temperature and incubated at 4C overnight with
one of the following primary antibodies: goat anti-sigma 1
receptor 1/150 (L20, Santa Cruz, sc16203), mouse anti-protein
disulphide isomerase (PDI) 1/250 (SPA 891, Stressgen), mouse
anti-non-phosphorylated neuroﬁlament H (SMI32) 1/500
(Covance), rabbit anti-peripherin 1/1000 (AB1530,
Millipore), mouse anti-cytochrome-c 1/500 (6H2.B4, BD
Biosciences) rabbit anti-GADD 153 (F-168): sc-575 (CHOP)
1/150 (Santa Cruz), rabbit anti-phospho-eIFa (Ser51) 1/200
(Cell Signaling Technology) and anti-phospho Histone H3
(Ser10) 1/1000 (Santa Cruz). Cells were washed three times
with PBS, then incubated with the appropriate secondary anti-
body (Invitrogen), washed three times with PBS, and launched
in VECTASHIELD mounting medium with DAPI (Vector).
Cells were observed under Zeiss Axiovision ﬂuorescence
microscope and analysed using either ImageJ or Axiovision
v4.8 software.
Proximity ligation assay
After ﬁxation and blocking, neurons were incubated overnight
with rabbit anti-IP3R3 (ITPR3) 1/250 (Chemicon) and mouse
anti-VDAC1 1/250 (Abcam) or rabbit anti-calreticulin 1/500
(ABR) and mouse anti-NeuN 1/500 (Millipore) primary anti-
bodies. After PBS wash, the proximity ligation assay (PLA)
probes anti-rabbit PLUS anti-mouse MINUS were added for
1 h in the antibody diluent buffer. If the two proteins of inter-
est were 40 nm or closer, connector oligonucleotides hybri-
dized with the PLA probes, and after ligation, the signal was
ampliﬁed by rolling circle ampliﬁcation. The Duolink detec-
tion ﬂuorophore red excitation/emission = 594/624 nm was
used. The ﬂuorescent spots (PLA signals) were analysed
using the plugin ‘analyze particles’ of ImageJ. As a negative
control, one of the primary antibodies was omitted, and the
PLA probe background staining was analysed. The back-
ground staining was limited for both probes.
Calcium imaging
To monitor quantitative changes of [Ca2+ ]i in motor neurons,
we used the ratiometric Fura 2-AM (Life Technologies) indi-
cator probe. Twenty-four hours after seeding, motor neurons
were treated or not with NE-100 and monitored by calcium
imaging 8 h later. Motor neurons were loaded with Fura-2
(4 mM) in a pH 7.4 solution containing: 150mM NaCl,
2mM KCl, 2mM MgCl2, 2mM CaCl2, 10mM HEPES, and
10mM glucose, for 20min in the dark at 37C, the dye was
then washed off and the coverslips reincubated in the dark for
a further 30min at room temperature to allow de-esteriﬁcation
of the dye. After loading, coverslips were transferred to an
inverted microscope Zeiss Axiovert 200M. To selectively visu-
alize motor neurons we ﬁrst used transmitted light and there-
after acquired ﬂuorescent images of Fura 2. Fura 2 was
alternately excited at 340 and 380nm and emission collected
at 510 nm. Images were acquired at 2 s intervals with
MetaFluor (Molecular Devices) on a 40 objective.
For [Ca2+ ] analysis we ﬁrst drew regions of interest on
motor neurons and then used them for analysis of Fura 2
images. [Ca2+ ] values were presented as the 340/380 nm
ratio. During experiments, neurons were perfused continuously
with external solution (0.5ml/min) using a peristaltic pump.
To invoke Ca2+ inﬂux, 25mM KCl was applied in external
solution (NaCl was replaced with equimolar amounts of KCl)
for 20 s. [Ca2+ ]i levels were calculated from the ratio of ﬂuor-
escent signals at excitation 340 and 380nm, and calibrated by
sequential addition of saturating CaCl2 (20mM) and EGTA
(20mM) in external solution after incubation with 10mM
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A23187 Ca2+ -ionophore (Sigma) and then translated to nano-
molar using the Grynkiewicz formula (Grynkiewicz et al.,
1985). Resting [Ca2+ ]c was determined as the average ratio
value between 30 and 180 s of recording. After KCl applica-
tion, the cells were perfused with the KCl-free solution for an
additional 3min to let them recover.
Mitochondrial axonal transport
Motor neurons were loaded with 25 nM of MitoTracker Red
CMXRos (Life Technologies) for 15min at 37C, then washed
with Neurobasal for 15min at room temperature.
Mitochondria movement was monitored on an inverted Zeiss
Axiovert 200M with a 63 objective using MetaMorph soft-
ware (Molecular Devices) and time-lapse imaged every 5 s for
10min. Time-lapse image stacks of 50 mm axon segments were
analysed using the ImageJ plugin Difference Tracker (Andrews
et al., 2010). The percentage of moving particles was deter-
mined using Difference Filter, which allowed extraction of the
moving pixels from the background stationary particles, based
on the intensity of pixel (chosen value: 10) and the comparison
of a number of offset frames (chosen value: 4). The velocity of
the particles was analysed using Mass particle tracker with
standard criteria (minimum tracked intensity: 20, minimum
feature size: 2, initial ﬂexibility: 10, subsequent ﬂexibility: 5
and minimal track length: 4). As an average, 20–30 axonal
segments were analysed per condition. Kymographs of selected
axons were realized using the ImageJ macro kymograph tool.
Reagents
For in vitro experiments, the following reagents were used:
SIGMAR1 antagonist (NE-100), agonist (Pre-084) and
Mdivi-1 were purchased from Tocris Biosciences.
Thapsigargin was purchased from Calbiochem, tunicamycin
and monastrol were from Sigma-Aldrich. salubrinal and 1,2-
bis(2-aminophenoxy)ethane-N,N,N,N-tetraacetic acid tetraki-
s(acetoxymethyl) ester (BAPTA/AM) were from Alexis
Corporation and z-Ala-Thr-Ala-Asp(OME)-fmk (z-ATAD-
fmk) was acquired from MBL International.
Immunohistochemistry
Mice were anaesthetized with a mixture of 10 ml/g of
Ketanarkon 100 (1mg/ml, Streuli) with 0.1% Rompun
(Bayer) in PBS then perfused transcardially with PBS followed
by paraformaldehyde (PFA) 4% in PBS. Spinal cords were
dissected out, incubated for 2 h in PFA 4% at 4C, and then
in 25% sucrose in PBS overnight. Tissues were embedded in
Optimal Cutting Temperature compound (Tissue-Tek).
Eighteen micrometre-thick cryosections were collected onto
SuperfrostTM Plus slides (Thermo Scientiﬁc), washed with
PBS, and incubated in the blocking solution (PBS, 4% BSA,
4% heat-inactivated goat or donkey serum, and 0.2%
TritonTM X-100) for 1–2 h. Sections were then incubated
with the appropriate primary antibodies overnight: rabbit
anti-PeiF2a 1/200 (Cell Signaling Technology), mouse anti-
non-phosphorylated neuroﬁlament H (SMI32) 1/500
(Covance), rabbit anti-cleaved caspase 3 (Cell Signaling
Technology), goat anti-MMP9 1/250 (Sigma-Aldrich) and
anti-mouse NeuN 1/500 (Millipore). Spinal cord sections
were washed three times with PBS, incubated with the
appropriate secondary antibody, washed three times with
PBS, and launched in Mowiol mounting medium. Pictures
were taken with a Zeiss Axiovision microscope (Zeiss) using
20 and 40 objectives. Immuno-quantiﬁcation was per-
formed using ImageJ software.
Tibialis anterior and soleus muscles were collected, then
post-ﬁxed for 20min in 4% PFA and incubated in the sucrose
solution overnight at 4C. Twenty-ﬁve micrometre sections of
tibialis anterior and 15 mm sections of soleus were incubated
for 5 h in PBS, 4% BSA, 0.5% TritonTM X-100 and anti-
Neuroﬁlament 145 (Millipore) was diluted at 1/200 in the
same solution and applied to slices for 2 days. Tissues were
washed with PBS, and secondary antibody and -bungarotoxin
CF594 (Biotium) were added at the same time for 2 h. Muscle
sections were then washed with PBS including as a ﬁnal step in
water and ﬁnally mounted in Mowiol. Pictures were taken
with a Zeiss Axiovision microscope (Zeiss) using 20 object-
ives and Z-stacks were performed to quantify the number of
denervated, partially innervated (intermediate) and innervated
neuromuscular junctions.
Western blot
Western blots were done on lysates from lumbar spinal cord
dissected from 2.5-month-old wild-type or Sigmar1 / mice.
Samples were lysed in a lysing buffer containing: 50mM Tris-
HCl, pH 7.5, 150mM NaCl, 2mM EDTA, 2mM EGTA, and
1% SDS supplemented with a protease inhibitor mixture
(Roche Molecular Biochemical). Protein concentration was
determined using the BCA kit (Pierce). Protein samples were
separated by SDS-PAGE and blotted to nitrocellulose mem-
branes (Schleicher and Schuell, Whatman International).
After blocking in 5% milk, the following primary antibodies
were used: mouse anti-SIGMAR1 1/100 (Santa-Cruz) and
mouse anti-actin (AC40, 1/20,000; Sigma). After incubation
of the blots with horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies, proteins were revealed using the chemilu-
minescent HRP substrate (Millipore). Immunoblot images were
quantiﬁed using the software ImageJ and normalized relative
to actin levels.
Electron microscopy
Animals were perfused with a mixture of 2% PFA and 2%
gluteraldehyde in sodium cacodylate buffer (0.1M). Lumbar
spinal cord was collected and post-ﬁxed for 3 h, washed in
0.1M cacodylate buffer, and osmicated for 4 h in 1% OsO4
(Fluka). Tissues were rinsed in 0.1M cacodylate buffer, dehy-
drated and embedded in epoxy 812-Araldite (Polysciences).
Ultra-thin sections were subsequently cut, collected on cello-
din-coated single slot grids and stained with uranyl acetate and
lead citrate. Photographs were obtained using a Tecnai G2
electron microscope. We quantiﬁed the number of mitochon-
dria displaying close contacts with ER and expressed it relative
to the total number of mitochondria per ﬁeld.
Statistical analysis
For survival and immune-quantiﬁcation experiments, differ-
ences were evaluated for their statistical signiﬁcance by
two-tailed, unpaired Student’s t-test. Values were expressed
as per cent  standard error of the mean (SEM). Signiﬁcance
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was accepted as the level of P5 0.05 (*P5 0.05, **P50.01,
and ***P5 0.001). For behavioural experiments, statistical
signiﬁcance was evaluated with a non-parametric
Mann-Whitney-U test. Values were expressed as the
mean  SEM. Signiﬁcance was accepted as the level of
P50.05 (*P50.05).
Results
Loss of SIGMAR1 function leads to
neuromuscular dysfunction in vivo
As SIGMAR1 dysfunction was shown to affect motor func-
tion both in mice and humans, we aimed at determining
whether this motor phenotype was related to motor neuron
degeneration. We conﬁrmed that Sigmar1 / mice displayed
motor coordination defects detected on accelerating rotarod
(Supplementary Fig. 1A and B) as previously described by
Mavlyutov et al. (2010). To assess whether these locomotor
defects were linked to muscle weakness, wemonitored muscle
strength of 5-month-old Sigmar1 / mice using the grid test
developed by Saxena et al. (2009). Muscle strength of
Sigmar1 / mice was signiﬁcantly lower compared to wild-
type mice (Fig. 1A). As muscle weakness is usually connected
to muscle denervation in motor neuron disease (Saxena et al.,
2009), we analysed the level of neuromuscular junction in-
nervation at different stages. At the age of 2.5 months,30%
of neuromuscular junctions were partially innervated, and at
the age of 5 months, 20% of neuromuscular junctions were
denervated in tibialis anterior (Fig. 1B and C). Interestingly,
no difference at the level of neuromuscular junctions between
wild-type and Sigmar1 / mice was observed in the slow-
twitch muscle, soleus (Supplementary Fig. 1C). The quantiﬁ-
cation of motor neurons in lumbar spinal cord highlighted a
small, but signiﬁcant, loss of motor neurons in 5-month-old
knockout animals (wild-type: 503  23, Sigmar1 /:
435  15) (Fig. 1D and E). Motor neuron degeneration was
also suggested by presence of cleaved caspase 3-positive
motor neurons in Sigmar1 / spinal cord sections
(Supplementary Fig. 1D). This low level of motor neuron
death may suggest the death of a subpopulation of motor
neurons. We therefore analysed the proportion of fast vulner-
able motor neurons, which are known to degenerate earlier in
the SOD1G93A ALS mouse model, based on their expression
of MMP9 (Kaplan et al., 2014). The mean number of highly
expressingMMP9motor neurons was signiﬁcantly decreased
in the ventral horn of 5-month-old Sigmar1 / mice (wild-
type: 3  0.25, Sigmar1 /: 1.8  0.34) indicating that this
motor neuronal population may be particularly affected by
loss of SIGMAR1 function (Fig. 1F and G).
Loss of SIGMAR1 function leads to
motor neuron degeneration in vitro
To characterize the underlying cellular mechanisms leading
to changes in motor neuron physiology, we cultured
primary embryonic motor neurons that have been previ-
ously successfully used as a model to identify cellular path-
ways in motor neuron disease (Bernard-Marissal et al.,
2012). In cultured motor neurons, SIGMAR1 was ex-
pressed in the soma and processes and co-localized with
the ER chaperone protein disulphide isomerase
(Supplementary Fig. 1E). To analyse the consequence of
SIGMAR1 dysfunction, we seeded motor neurons extracted
either from wild-type and Sigmar1 / mouse embryos or
wild-type rat embryos treated with a selective antagonist
and agonist of SIGMAR1, NE-100 and Pre-084, respect-
ively (Hayashi and Su, 2007). Both NE-100 treated motor
neurons and Sigmar1 / motor neurons showed a signiﬁ-
cant reduction (20–30%) in axonal length compared to
controls (Fig. 2A and B). To ensure that the observed
axonal length reduction was the consequence of axonal
degeneration rather than a defect in axonal growth, we
stained motor neurons with peripherin, which is known
to label axonal swellings and spheroids (Corbo and Hays,
1992). We observed a signiﬁcant increase in the number of
large axonal swellings at the end terminals of NE-100-trea-
ted motor neurons and Sigmar1 / motor neurons (none:
0.8  0.2, NE-100: 2.15  0.3 P = 0.013; wild-type:
1.2  0.3 and Sigmar1 /: 3.4  0.4, P = 0.0003) (Fig.
2B and C). This axonal degeneration was followed a few
hours later by 40% of motor neuron cell death (Fig. 2D)
in both SIGMAR1 dysfunction conditions suggesting a
dying-back degeneration. Importantly, treating motor neu-
rons with a speciﬁc SIGMAR1 agonist, Pre-084, prevented
both axonal degeneration (Fig. 2C) and the death induced
by NE-100 (Fig. 2D). Importantly, NE-100 and Pre-084
have no effect on the survival of Sigmar1 / motor neu-
rons, conﬁrming their speciﬁcity for SIGMAR1
(Supplementary Fig. 1F). Finally, the observed effect of
NE-100 was speciﬁc for motor neurons. Indeed, sensory
neurons survival was not affected even when treated with
higher doses of NE-100 (Fig. 2D).
ER–mitochondria disconnection is
observed both in in vitro and in vivo
models of loss of SIGMAR1 function
SIGMAR1 is localized at the outer membrane of the ER at
speciﬁc contact points between ER and mitochondria called
MAMs (Hayashi and Su, 2007). As SIGMAR1 dysfunction
has been previously connected to MAM disturbances
(Hayashi and Su, 2007), we quantiﬁed the level of
MAMs in motor neuron cultures. As the distance between
ER and mitochondria at MAMs is 10–20 nm (Csordas
et al., 2006), we used an in situ proximity ligation assay
(De Vos et al., 2012; Hedskog et al., 2013). Cultured
motor neurons were probed with anti-ITPR3 (ER side)
and anti-VDAC1 (mitochondrial side) primary antibodies
followed by hybridization with secondary antibodies
coupled to different oligonucleotides that hybridize together
if the distance between two antibody-coupled
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oligonucleotides (and hence the targeted proteins) is
540 nm. As a control we applied only one of the two
antibodies or we used antibodies targeting non-interacting
proteins (anti-calreticulin, an ER protein, and anti-NeuN, a
nuclear protein) (Fig. 3A). We did not observe any inter-
actions (dots) under these conditions. The number of
ITPR3–VDAC1 interactions were decreased both in
the cell body and in axons of NE-100 treated and
Sigmar1 / motor neurons (cell body: NE-100:
61.3  7.5% and Sigmar1 /: 51  10%, axon: NE-100:
44.2  17% and Sigmar1 /: 30.3  7%, relative to their
respective controls) as well as after thapsigargin treatment,
which was previously shown to disturb mitochondria–ER
connections (Goetz et al., 2007) (Fig. 3A and B). In lumbar
spinal cord of 2.5-month-old mice processed for electron
microscopy, we evaluated, in motor neurons, the number of
mitochondria apposed to the ER relative to the total
number of mitochondria unapposed to the ER, per ﬁeld.
In controls, a mean fraction of 30% of MAMs was
observed whereas in Sigmar1 / the MAMs fraction was
18% (Fig. 3C and D).
Defective calcium homeostasis and
ER stress activation contribute to
neuronal degeneration linked to
SIGMAR1 dysfunction
At the level of MAMs, ER transfers calcium towards the
mitochondria and this is necessary for its metabolic func-
tion (Rizzuto et al., 2012), and the disruption of MAM
proteins is sufﬁcient to induce calcium defects (De Vos
et al., 2012). We monitored the concentration of intracel-
lular calcium, [Ca2+ ]i, using ratiometric Fura 2 imaging.
Figure 1 SIGMAR1 deficiency leads to motor neuron degeneration in vivo. (A) Grid test evaluation of muscle strength in 5-month-old
wild-type (n = 6) and Sigmar1 / (n = 7) mice. Values are expressed as mean score  SEM. *P5 0.05. P-value represents the significance between
the histogram bars under the two ends of the horizontal line above them. (B) Level of muscle innervation of tibialis anterior in wild-type and
Sigmar1 / mice (2.5- and 5-month-old) quantified by the co-localization between a nerve terminal marker (NF-145) and acetylcholine receptor
(-bungarotoxin). Results are expressed as the percentage of innervated, intermediate or denervated neuromuscular junctions/total of neuro-
muscular junctions  SEM from n = 3 mice, *P5 0.05, **P5 0.01. (C) Examples of NF-145 and -bungarotoxin staining of neuromuscular
junctions (NMJ) in control (wild-type) and Sigmar1 / preparations. (D) Section of spinal cord from wild-type and Sigmar1 / mice stained by
Nissl coloration. (E) Survival of motor neurons in lumbar portion of the spinal cord was evaluated on 44 spinal cord sections per mouse. (F)
Section of spinal cord from 5 month-old wild-type and Sigmar1 / mice stained for NeuN and MMP9 proteins. (G) Quantification of the number
of MMP9 and NeuN positive motor neurons. The data are expressed as mean  sem (n = 4 mice per genotype), *P5 0.05. MN = motor neuron.
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To ensure that only viable cells were analysed, we induced
a transient Ca2+ inﬂux by depolarization with 25mM KCl.
Only cells that showed a transient increase in [Ca2+ ]i were
included in the analyses of resting [Ca2+ ]i and decay time.
In NE-100 treated motor neurons, resting [Ca2+ ]i was sig-
niﬁcantly elevated (wild-type: 56  0.07 nM, NE-100:
85  0.2 nM) (Fig. 4A and B). We detected no signiﬁcant
difference between wild-type and NE-100 motor neurons in
their response to the KCl stimulus (Fig. 4A).
However, the time to return to basal levels was signiﬁcantly
longer (20 s) in NE-100 treated motor neurons than in
controls (Fig. 4C). These results suggest that inhibiting
SIGMAR1 function dysregulated intracellular calcium
homeostasis.
Because defects in calcium handling in motor neurons has
been previously associated with ER stress activation
(Bernard-Marissal et al., 2012) and loss of SIGMAR1 func-
tion has been shown to induce ER dysfunction in cultured
NSC-34 cells (Prause et al., 2013), we analysed the level of
expression of three ER stress indicators: phosphorylated
EIF2A (phosphorylated following PERK activation),
CHOP (C/EBP homologous protein, transcribed following
PERK activation) and PDI in control and mutant condi-
tions. These markers were signiﬁcantly increased in
NE-100 treated motor neurons and in Sigmar1 / motor
neurons as compared to their controls (Fig. 4D and E) but
ER stress level was unchanged in dorsal root ganglia
NE-100 treated neurons (Supplementary Fig. 2). As phos-
phorylated EIF2A is an early-activated ER stress marker we
analysed its expression in lumbar spinal cord motor neu-
rons of 2.5- and 5-month-old wild-type and Sigmar1 /
mice. We observed that phosphorylated EIF2A expression
was strongly upregulated in spinal motor neurons of the
Sigmar1 / mice (Fig. 4D and F).
To determine whether the altered calcium homeostasis
and ER stress play a functional role in motor neuron de-
generation, motor neurons were cultured with or without
NE-100 in combination or not with: a cytoplasmic calcium
scavenger (BAPTA-AM), an ER stress inhibitor (salubrinal)
or an inhibitor of the ER connected caspase-12 (Z-ATAD-
fmk). The chelation of calcium and abrogation of ER stress
signiﬁcantly reduced axonal degeneration (NE-100:
1845  230mm, NE-100 + BAPTA-AM: 2424  224mm;
NE-100 + salubrinal: 2495  145mm) (Fig. 4G) as well as
Figure 2 SIGMAR1 deficiency leads to motor neuron degeneration in vitro. (A) Wild-type, NE-100 treated and Sigmar1 / motor
neurons were stained with a specific motor neuron marker SMI32 and axonal length was measured using Neuron J plugin. Data are expressed as
the mean  SEM of three independent experiments. *P5 0.05, **P5 0.01, ***P5 0.001. (B) Examples of SMI32 and peripherin stainings of
control and NE-100 treated motor neurons. (C) Number of axonal swellings per axons in wild-type, NE-100 (300 nM), Pre-084 (50 nM) or Pre-
084 + NE-100 treated motor neurons. (D) Motor neuron and sensory neurons (dorsal root ganglias) survival was assayed 24 h after treatment of
wild-type rat motor neurons with SIGMAR1 antagonist NE-100 (300 nM for motor neurons and 1 mM for dorsal root ganglia neurons) or agonist
Pre-084 (50 nM) or 24 h after plating of mouse wild-type and Sigmar1 / motor neurons. Data represent mean  SEM of three independent
experiments. *P5 0.05, **P5 0.01, ***P5 0.001.
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motor neuron death (NE-100: 60.3  7.4%, NE-
100 + BAPTA-AM: 80.7  8%; NE-100 + salubrinal:
101.6  7.6% and NE-100 + Z-ATAD-fmk: 94.8  9.4%)
(Fig. 4H).
We observed thus far that loss of function of SIGMAR1
compromises both calcium homeostasis and ER function
leading to motor neuron degeneration. Both changes
occur early (8 h after NE-100 treatment), but the relation
between these two cellular defects remained unclear. We
therefore measured intracellular calcium, [Ca2+ ]i and phos-
phorylated EIF2A level in NE-100 treated motor neurons in
combination or not of BAPTA-AM or salubrinal. Addition
of either BAPTA-AM or salubrinal to motor neurons abro-
gated the increase of resting [Ca2+ ]i observed in NE-100
condition leading to a [Ca2+ ]i below control levels (wild-
type: 58.2  1.4 nM, NE-100: 98.02  2.5 nM, NE-
100 + BAPTA-AM: 40  3.3 nM, NE-100 + salubrinal:
37.8  1.3 nM) (Fig. 5A). The increase in phosphorylated
EIF2A expression level observed in NE-100 was signiﬁ-
cantly reduced after salubrinal addition (wild-type:
100  0 %, NE-100: 140.9  10.7%, NE-100 + salubrinal:
57.5  22) (Fig. 5B and C). However, the co-treatment of
motor neurons with NE-100 and BAPTA-AM did not sig-
niﬁcantly change the expression of phosphorylated EIF2A
compared to the NE-100 condition (Fig. 5B and C). These
observations suggest that ER stress acts through calcium
homeostasis impairment to trigger Sigmar1 / motor
neuron death.
Mitochondrial dysfunction is involved
in the motor neuron degeneration
process
At MAMs, ER tubules have been recently shown to circum-
scribe the mitochondria thus promoting mitochondrial ﬁs-
sion (Westermann, 2011). Moreover, [Ca2+ ] regulates the
level of phosphorylation of the key ﬁssion protein, the
dynamin 1-like protein (Drp1, now known as DNM1L)
(Dickey and Strack, 2011). To analyse mitochondrial
morphology, we loaded motor neurons with
MitoTracker Red allowing us to target 97% of axonal
mitochondria (Supplementary Fig. 3C and D) and measure
the mitochondrial length. We noticed a signiﬁcant (30%)
increase in the mean mitochondrial size in both NE-100
treated and Sigmar1 / motor neurons (Fig. 6A and B).
The distribution of mitochondria according to their size
highlights a signiﬁcant increase in the proportion of mito-
chondria 43 mm in length (wild-type: 11  3.3%, NE-100:
22  2.4%). Conversely, a decrease in the proportion of
Figure 3 Inhibition and loss of SIGMAR1 function reduce contacts between mitochondria and ER in motor neurons both
in vitro and in vivo. (A) Examples of mitochondria-ER contact analysis done in vitro, on purified motor neurons, using a proximity ligation assay.
The red dots indicate proximity of the ER and mitochondria targeted respectively with an anti-ITPR3 (IP3R3) and anti-VDAC1 antibody. Anti-
calreticulin (CRT) -anti-NeuN and anti-ITPR3 alone were used as negative controls. (B) Quantification of the proximity ligation assay results on
wild-type, NE-100 (300 nM) and thapsigargin (10 nM) treated motor neurons and wild-type and Sigmar1 / motor neurons. Data were analysed
using Image J and expressed as percentage  SEM relative to control (n = 3; *P5 0.05, **P5 0.01). (C) Examples of electron microscopy pictures
of ER-mitochondria contacts in spinal motor neurons of wild-type and Sigmar1 / mice. Asterisk indicates a MAM. (D) Quantification of
mitochondria apposed on ER (n = 3 animals per genotype, *P5 0.05).
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Figure 4 Calcium signalling and ER stress are involved in motor neuron degeneration induced by SIGMAR1 deficiency. (A)
Intracellular calcium concentration [Ca2 + ]i was determined in motor neurons after 8 h of NE-100 treatment by Fura 2 ratio imaging. Resting
[Ca2 + ]i was calculated for each individual neuron as the average resting [Ca2 + ]i between 30 and 180 s of measurement (grey box). (B)
Representation of [Ca2 + ]i values determined by averaging the data obtained from individual cells. (C) Representation of half decay time (50%
return to basal level) analysis. Data are from four experiments with 20 neurons analysed per condition (values are mean  SEM). (D) The level
of ER stress was evaluated by marker phosphorylated EIF2A (P-eif2a) in cultured motor neurons (left) and on motor neurons of the lumbar spinal
cord (right). (E) Wild-type rat motor neurons treated with NE-100 (300 nM) and cultured wild-type and Sigmar1 / motor neurons were fixed
and immunostained for ER stress markers (phosphorylated EIF2A, CHOP and PDI), in combination with a motor neuronal marker SMI32. The
data represent mean intensity values of ER stress marker and are presented as a percentage change compared to control values arbitrarily set to
100%. (F) Phosphorylated EIF2A staining was used to quantify ER stress level in spinal motor neurons of 2.5 and 5-month-old wild-type and
Sigmar1 / mice and is represented as a change  SEM compared to wild-type values arbitrarily set to 100%. (G) Motor neurons were treated
with NE-100 (300 nM) in the presence or not of BAPTA-AM (5 mg/ml), a calcium chelator, or the ER stress inhibitor salubrinal. After 8 h of
treatment, motor neurons were stained with SMI32 and axonal length was quantified. Values are mean  SEM from three independent experi-
ments, *P5 0.05, **P5 0.01. (H) Motor neurons were treated with NE-100 (300 nM) in combination or not with either BAPTA-AM, a calcium
chelator, salubrinal (10mM), an ER stress inhibitor or z-ATAD-fmk (10 mM), a caspase 12 inhibitor. Motor neuron survival was evaluated 24 h after
treatment and expressed as percentage of control  SEM. All data represent the mean of three independent experiments, *P5 0.05, **P5 0.01,
***P5 0.001.
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mitochondria of 1–2mm in length was observed in cells
treated with SIGMAR1 antagonist (wild-type: 54  3.7%,
NE-100: 38  2.3%) (Fig. 6C). To determine whether the
observed mitochondrial phenotype was a major effector in
the axonal degeneration process in SIGMAR1 deﬁcient
motor neurons, we reproduced the size increase in mito-
chondria by using Mdivi-1, a selective inhibitor of
DNM1L that blocks mitochondrial ﬁssion (Cassidy-Stone
et al., 2008). In motor neurons, mitochondrial length in-
creases proportionally to Mdivi-1 concentration
(Supplementary Fig. 3A and B). Importantly, when motor
neurons were treated for 8 h with Mdivi-1 (10 mM), they
showed a signiﬁcant reduction in axonal length (Fig. 6D).
At low doses (5 and 10 mM of Mdivi-1), motor neuron
survival was of 80.7  5.9% and 69.7  0.8%, respectively
relative to non-treated cells. At these concentrations we did
not detect any changes in sensory neurons survival
(Fig. 6E). At 20 mM, Mdivi-1 decreased motor neuron
and sensory neurons survival by 40% and 20%, respect-
ively (Fig. 6E). These last data suggest that motor neurons




Defects in axonal transport of mitochondria have been
observed in several models of motor neuron diseases and
are usually connected to axonal degeneration (De Vos
et al., 2008). As we observed elongated mitochondria and
axonal degeneration following SIGMAR1 dysfunction, we
considered whether this could result in mitochondrial trans-
port impairment. We performed time-lapse experiments on
MitoTracker Red loaded motor neurons and monitored
mitochondrial transport in different conditions using a
fully automated analysis with Difference Tracker plugin
of ImageJ (Andrews et al., 2010). We observed a signiﬁcant
decrease in the proportion of motile particles between non-
treated (19  1.3%) and NE-100 treated cultured neurons
(15  1.2%), and between wild-type (15.2  1.8%) and
Sigmar1 / neurons (8.6  1%) as well as in neurons trea-
ted with Mdivi-1 (14.6  1.6%) (Fig. 7A and B). As a
positive control we used monastrol, which speciﬁcally af-
fects the anterograde transport by inhibiting kinesin 5
family proteins (Sunil et al., 2012) leading to a decrease
in motile particles in motor neurons (12  1.4%) (Fig.
7B). Our additional more detailed study of mitochondrial
movement showed a signiﬁcant and speciﬁc decrease in the
velocity of retrograde mitochondria in conditions of defect-
ive SIGMAR1 (Fig. 7C), which could explain the observed
accumulation of distal mitochondria (Fig. 7D). Surprisingly,
the inhibition of mitochondrial ﬁssion by Mdivi-1 does not
affect mitochondrial velocity in any direction. This suggests
that the dysregulation of retrograde mitochondrial trans-
port could depend on other cellular mechanisms.
Calcium homeostasis defects and ER
stress contribute to mitochondrial
dysfunction
Intracellular calcium has been shown to inﬂuence mito-
chondrial motility by regulating the attachment of docking
Figure 5 Evaluation of ER stress and calcium homeostasis crossregulation induced by SIGMAR1 deficiency. (A) Intracellular
calcium concentration [Ca2 + ]i was determined in motor neurons after 8 h of NE-100 (300 nM) in combination or not with salubrinal (10 mM) or
BAPTA-AM (5mg/ml) treatment by Fura 2 ratio imaging. Resting [Ca2 + ]i was calculated for each individual neuron as the average resting [Ca2 + ]i
between 30 and 180 s of measurement. [Ca2 + ]i values determined by averaging the data obtained from individual cells are represented. (B) The
level of ER stress was evaluated by marker phosphorylated EIF2A in cultured motor neurons treated with NE-100 (300 nM) in combination or not
with salubrinal (10mM) or BAPTA-AM (5 mg/ml). (C) The data represent mean intensity values of phosphorylated EIF2A and are presented as a
percentage change compared to control values arbitrarily set to 100%. IF = immunofluorescence.
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proteins Miro/Milton to motor proteins and microtubules
(Sheng, 2014). As we noticed an increase in intracellular
calcium associated with ER stress, we wondered whether
these impairments can contribute to mitochondrial defects
and motor neuron degeneration. After inhibiting SIGMAR1
function using NE-100, we treated motor neurons either
with BAPTA-AM, a selective intracellular calcium chelator,
or with an ER stress inhibitor salubrinal. The reduction in
calcium overloading and ER stress level restored mitochon-
drial mean length (wild-type: 1.67  0.11mm, NE-100:
2.12  0.14mm, NE-100 + BAPTA-AM: 1.88  0.05mm,
NE-100 + salubrinal: 1.7  0.08mm) (Fig. 8A). In recent
studies, SIGMAR1 loss has been correlated to ER stress
activation and an increase in unfolded protein response
(Prause et al., 2013). To determine whether the elongation
of mitochondria depends on an ER stress as a result of
protein unfolding or of ER calcium disturbance, we treated
motor neurons with subtle doses of two well-known ER
stress inducers: thapsigargin (5 nM), which depletes ER cal-
cium stores and tunicamycin (0.5 mg/ml), which impairs ER
protein folding (Bernard-Marissal et al., 2012).
Interestingly, mitochondrial length was signiﬁcantly
increased only after thapsigargin treatment (none:
1.58  0.04mm, thapsigargin: 2.12  0.3 mm, tunicamycin:
1.64  0.09mm) (Fig. 8B). Addition of BAPTA-AM sup-
pressed mitochondria elongation induced by thapsigargin
(Fig. 8B). These data highlighted the importance of ER cal-
cium homeostasis rather than ER protein folding in the
modulation of mitochondria morphology. We also moni-
tored mitochondria axonal transport in the presence or ab-
sence of BAPTA-AM (5mg/ml). Enhancing calcium
buffering was not able to improve the proportion of
moving mitochondria; however, it restored the velocity of
retrograde-moving mitochondria (Fig. 8C and D). This sug-
gests that the observed protective effect on motor neuron
survival after chelation of intracellular calcium may, in
part, reduce motor neuron degeneration by increasing mito-
chondria velocity.
Discussion
In this study we focused on the role of one of the MAM
proteins, SIGMAR1, in motor neuron function. SIGMAR1
disturbance have critical consequences in humans as patho-
genic mutations in SIGMAR1 have been identiﬁed in
FTLD-ALS and juvenile ALS cases (Luty et al., 2010; Al-
Saif et al., 2011). Here, we demonstrated that loss/impair-
ment of SIGMAR1 leads to axonal and motor neuron
degeneration both in vitro and in vivo. This was connected
to MAM loss, calcium homeostasis impairment, ER stress
activation, elongated mitochondria and defective mitochon-
drial transport.
In some models of motor neuron disease, motor neurons
are thought to die through a dying-back degeneration pro-
cess (Fischer et al., 2004; Pun et al., 2006). This phenom-
enon is initiated by a dysfunction of the axonal periphery,
Figure 6 Deficit in mitochondrial dynamics induced by
SIGMAR1 dysfunction triggers axonal degeneration and
cell death. (A–C) NE-100 (300 nM) treated motor neurons or
Sigmar1 / motor neurons were loaded with MitoTracker Red
allowing staining of mitochondria. (A) Example of MitoTracker
Red-labelled mitochondria in control and NE-100 treated motor
neurons. Mitochondrial length was measured in the proximal part of
the axon and data were expressed as mean length of mitochondria
(B) or expressed as a percentage of mitochondrial size category
(C). (D) Axonal length was determined 8 h after Mdivi-1 treatment.
Data represent the mean  SEM. (E) Representation of motor
neuron and sensory neurons survival after 24 h of treatment with
various concentrations of Mdivi-1. Data are represented as
percentage  SEM relative to control. *P5 0.05, **P5 0.01,
***P5 0.001.
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which is followed by a progressive distal-to-proximal de-
generation of the whole axon. In various models presented
in this study, we observed features of axonal degeneration
a long time before the loss of somas. In cultured motor
neurons, axonal length was reduced as soon as 8 h after
inhibition of SIGMAR1 with NE-100 or 16 h after plating
of Sigmar1 / motor neurons, whereas decrease in motor
neuron survival was observed 24 h post-treatment or plat-
ing. Axonal length reduction probably reﬂects a process of
axonal degeneration since we observed the presence of
axonal swellings at the terminals of the axons as previously
described in other motor neuron disease models (Selvaraj
et al., 2012).
Our behavioural characterization of Sigmar1 / mice
conﬁrmed the previously described impairment in the
rotarod test (Mavlyutov et al., 2010). Interestingly, we
also noticed a decrease in muscle strength in these mice
scored by the grid test. In contrast to other motor neuron
disease models such as the SOD1G93A mice, the defects in
the Sigmar1 / mice are relatively subtle. Importantly, we
connected for the ﬁrst time the appearance of motor defects
in Sigmar1 / mice to neuromuscular dysfunction. Indeed,
one-third of neuromuscular junctions were partially dener-
vated in the fast-twitch muscle tibialis anterior at the age of
2.5 months, and 20% completely denervated at 5-months.
Although we did not notice motor neuron death at 2.5
months, we observed a small but signiﬁcant loss of motor
neurons in the lumbar spinal cord of Sigmar1 / mice at
the age of 5 months. This last result was in line with a
dying-back hypothesis in SIGMAR1 linked motor neuron
degeneration. Interestingly, the slow-twitch muscle soleus of
5-month-old Sigmar1 / mice was not affected, which may
suggest a higher susceptibility of fast-fatigable ﬁbres to de-
generate as previously observed in other motor neuron dis-
ease models (Pun et al., 2006). In agreement with this
hypothesis, motor neurons highly expressing MMP9 were
selectively lost in the ventral horn of 5-month-old
Sigmar1 / mice. Neuronal MMP9 was recently demon-
strated as a determinant of the selective degeneration of fast
vulnerable motor neurons in the SOD1G93A ALS mouse
Figure 7 SIGMAR1 dysfunction disrupts mitochondrial axonal transport. (A) Representative kymographs show mitochondrial
transport in control and NE-100 treated motor neurons. (B) The percentage of motility particles in control and NE-100, Mdivi-1 and monastrol
treated motor neurons and in motor neurons isolated from control and Sigmar1 / mice. (C) Anterograde and retrograde velocity of
mitochondria was determined in depicted motor neuron cultures. Data are from five experiments with 25–35 neurons analysed, *P5 0.05.
(D) Number of mitochondria in proximal and distal axonal segments was quantified in mitotracker-red loaded motor neurons treated or not
with NE-100. Data were expressed as mean number of mitochondria per 100 mm of axon  SEM. *P5 0.05.
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model (Kaplan et al., 2014). Therefore our results suggest a
role of SIGMAR1 in the vulnerability of a subpopulation of
motor neurons.
At MAMs, SIGMAR1 is known to control calcium trans-
fer from ER to the mitochondria by interacting with ITPR3
thus contributing to the stabilization of this receptor during
elevated calcium transfer. In the absence of SIGMAR1,
ITPR3 is prone to degradation and is thus unable to
ensure proper calcium transfer (Hayashi and Su, 2007).
We observed an important loss of contacts between the
two organelles in motor neurons in the absence of
SIGMAR1 as well as abnormalities in calcium homeostasis
with, notably, an increase of basal calcium a few hours
following SIGMAR1 inhibition and an increase in the
time required to recover from KCl depolarization. These
observations clearly indicate a defect in calcium extrusion
and/or calcium buffering when SIGMAR1 function is af-
fected. Interestingly, the deletion/mutation of other MAM
protein-coding genes, such as VAPB and MFN2 (mitofusin
2), has been shown to impair calcium homeostasis leading
to a reduction of calcium mitochondria uptake, increase of
intracellular calcium as well as ER calcium overload (de
Brito and Scorrano, 2008; De Vos et al., 2012), underlining
the importance of MAMs in calcium homeostasis regula-
tion. In parallel to calcium homeostasis defects, we
observed an increase in ER stress following SIGMAR1
loss both in vitro and in vivo. Previous work connected
the absence of SIGMAR1 chaperoning function to ER dys-
function and ER stress (Prause et al., 2013). Surprisingly,
inhibition of ER stress by salubrinal led to abrogated cyto-
plasmic calcium increase while the calcium chelator
BAPTA-AM was not able to reduce ER stress level, placing
ER stress upstream of calcium homeostasis defects. Besides
its role in phosphorylated EIF2A dephosphorylation, salu-
brinal is known to upregulate ATF4 (Wu et al., 2014). It is
therefore possible that salubrinal modulates calcium level
through the ATF4-anti apoptotic protein GRINA pathway,
as previously demonstrated by Matus et al. (2013).
Under stress conditions, mitochondria maintain their
function by dividing or fusing: mitochondrial fusion en-
ables the exchange of contents between mitochondria,
allowing defective mitochondria to regain components of
the respiratory chain, whereas mitochondrial ﬁssion is
required for proper mitochondrial transport and also facili-
tates apoptosis (Milone and Benarroch, 2012). We noticed
an increase in mitochondrial length in axons of motor neu-
rons following inhibition or loss of SIGMAR1. This in-
crease did not result from a general increase of the length
of all mitochondria but corresponded to a signiﬁcant en-
richment of very long mitochondria (with size 43 mm) con-
comitant to a loss of smaller mitochondria (52 mm).
Inducing artiﬁcially elongated mitochondria using a select-
ive inhibitor of ﬁssion, Mdivi-1, was sufﬁcient to induce
axonal degeneration and motor neuron death. This obser-
vation supports the importance of a dysregulation of mito-
chondrial dynamics in SIGMAR1-linked motor neuron
degeneration. This function is regulated by different types
of dynamin-like guanosine triphosphate (GTP)-ases and
indeed several of them have been found mutated or affected
in different neurological disorders (Baxter et al., 2002;
Chung et al., 2006; Waterham et al., 2007). In particular,
a dominant-negative mutation in DNM1L, which is
involved in the mitochondrial ﬁssion process, has been
associated with a fatal birth defect in humans (Waterham
et al., 2007). We did not notice a change in the level of
expression/activation of DNM1L in our conditions (data
not shown) suggesting the implication of other regulating
ﬁssion/fusion protein(s) or other mechanisms. Alternatively,
SIGMAR1 dysfunction could disturb the mitochondrial ﬁs-
sion process via ER/mitochondrial disconnection. Indeed,
the ER has been shown recently to participate in the mito-
chondrial ﬁssion process at MAMs by circumscribing the
mitochondria (Westermann, 2011). We observed a reduc-
tion of mitochondria-ER connections both in vitro and
in vivo in motor neurons deﬁcient for SIGMAR1. The
observed disconnection of the two organelles could
Figure 8 Intracellular calcium level and ER stress modu-
late various mitochondrial parameters in motor neurons.
(A) Mitochondrial size was determined in motor neurons treated
with NE-100 (300 nM) in presence or absence of BAPTA-AM (5mg/
ml) or salubrinal (10mM). (B) Mitochondrial size was determined in
motor neurons treated with two ER stress inducers thapsigargin
(5 nM, ER calcium depletor) and tunicamycin (0.5 mg/ml, protein
folding inhibitor) and the calcium chelator BAPTA-AM (5 mg/ml). (C)
Motility events were quantified in motor neurons treated with NE-
100 in combination with BAPTA-AM (5 mg/ml). (D) Mitochondrial
velocity was quantified in motor neurons treated either with NE-
100 or BAPTA-AM (5 mg/ml), then in combination with both. Data
are expressed as means  SEM. The data presented under ‘None’
and ‘NE-100’ are the same as in Fig. 7C. *P5 0.05.
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therefore reduce the efﬁciency of the mitochondrial ﬁssion
process leading to hyperfused mitochondria.
In addition to mitochondrial ﬁssion and fusion defects,
mitochondrial dysfunction has been previously linked to
axonal transport alteration in various disorders (Misko
et al., 2012). Anterograde axonal transport allows bringing
mitochondria to critical energy dependent sites, whereas
retrograde transport takes care of driving mitochondria
back to the cell body for repair or destruction. We
observed that the SIGMAR1 inhibition in particular affects
the retrograde mitochondrial velocity. Interestingly, in a
mouse model of ALS, retrograde transport was reported
to be selectively affected 2 months before the appearance
of symptoms (Bilsland et al., 2010). We observed an accu-
mulation of mitochondria at the periphery of the axon, a
phenomenon already identiﬁed in vivo in mice expressing a
mutated form of the mitochondrial/MAM MFN2 protein
(Cartoni et al., 2010). It is possible that the observed mito-
chondrial accumulation reﬂects the consequence of the de-
fects in retrograde transport.
Detected changes in mitochondrial size may reﬂect acti-
vation of a protective mechanism in SIGMAR1 affected
motor neurons. Stress-induced mitochondrial hyperfusion
was shown to increase ATP availability, avoiding mito-
phagy and promoting cell survival (Tondera et al., 2009).
However, it might be also a causative element in retrograde
transport impairment because large mitochondria may be
difﬁcult to move back to the cell body for degradation and
recycling. Previous studies done on cultured neurons ex-
pressing mutated MFN2 described defects in mitochondrial
transport, a reduction in mitochondrial size and axonal
degeneration (Misko et al., 2010). Interestingly, the knock-
down of OPA1, which disrupts mitochondrial fusion lead-
ing to generation of mitochondria with reduced size, was
not sufﬁcient to recapitulate axonal degeneration induced
by presence of mutated MFN2 suggesting that the dysregu-
lation of mitochondrial fusion is not sufﬁcient to initiate
axonal degeneration (Misko et al., 2012). In our case, ar-
tiﬁcially increasing mitochondrial size by Mdivi-1 was suf-
ﬁcient to reproduce the consequence of the inhibition/loss
of SIGMAR1 leading to a decreased proportion of moving
mitochondria and axonal degeneration. These results are in
accordance with previous literature showing that the inhib-
ition of DNM1L results in enlarged mitochondria that are
not localized properly in dendrites or axons (Kageyama
et al., 2012). Although inhibiting ﬁssion led to a decrease
in the number of moving mitochondria, it did not impact
the velocity of the population of moving mitochondria in
any of the transport directions, contrary to changes induced
by inhibition/loss of SIGMAR1.
The inhibition of ﬁssion induced by inhibition/loss of
SIGMAR1 and Mdivi-1 treatment leads to an increase in
the population of very elongated mitochondria (43 mm)
that are probably not able to move at all. Interestingly,
we observed that chelation of calcium restored the retro-
grade velocity of the remaining moving mitochondria, but
did not rescue the number of moving mitochondria.
Calcium level has been already shown to inﬂuence mito-
chondrial axonal transport by regulating the mitochondrial
transport machinery via the mitochondrion adaptor Miro
(Rizzuto et al., 2012). Elevation of cytosolic calcium is
thought to slow down moving mitochondria in the axons
at sites lacking ATP. It is therefore possible that disturbed
calcium homeostasis, which is a consequence of inhibition/
loss of SIGMAR1 function, might account for the decrease
of velocity of moving mitochondria.
In all experiments, we observed a speciﬁc degeneration of
motor neurons following inhibition/loss of SIGMAR1 as
compared to sensory neurons. Although SIGMAR1 has
been previously shown to be expressed in myelinating
glial cells (Palacios et al., 2004) known to have a critical
role in motor neuron survival (Lee et al., 2012), we did not
observe any defects in Schwann cell survival and prolifer-
ation under SIGMAR1 loss of function conditions
(Supplementary Fig. 4A and B). Our results are in accord-
ance with the phenotype of SIGMAR1 affected patients
who display motor disabilities with no alteration of sensory
functions or signs of demyelination (Luty et al., 2010; Al-
Saif et al., 2011). This could be explained by a lower sen-
sitivity of sensory neurons and Schwann cells to SIGMAR1
loss. Recent data demonstrated that the knock-down of
SIGMAR1 in hippocampal neurons was sufﬁcient to
induce axonal degeneration but not the cell loss (Hedskog
et al., 2013). Similar differences were observed for other
cell types: lens cells died after SIGMAR1 antagonist treat-
ment whereas ﬁbroblasts were resistant and it was pro-
posed that cell sensitivity to calcium response following
SIGMAR1 inhibition may underlie these differences
(Spruce et al., 2004; Wang and Duncan, 2006; Prause
et al., 2013). Motor neurons are known to be prone to
degenerate following disturbance in calcium homeostasis.
Their low content in calcium buffering proteins such as
calreticulin has been recently demonstrated as a factor of
their vulnerability both in vitro and in vivo (Bernard-
Marissal et al., 2015). Interestingly, calpastatin, an inhibi-
tor of calcium-dependent cysteine protease, has been shown
to reduce the toxicity of SOD1G93A in motor neurons
in vitro (Tradewell and Durham, 2010).
Together, our results provide an important insight into
the role of SIGMAR1 mediated ER–mitochondria inter-
actions in motor neuron function. These ﬁndings may
open new perspectives for the development of future thera-
pies for patients with defects in SIGMAR1 function and
more generally, in the ﬁeld of motor neuron disease.
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